In Belgium, the sales of antiarrhythmic medicines have shown a noticeable declining trend over the past decade. From a peak of €15.5 million in 2014, sales have steadily decreased to €13.2 million in 2023. This represents a year-on-year decline of approximately -1.49% for 2023. Notably, the Compound Annual Growth Rate (CAGR) calculated over the last five years stands at -2.39%, indicating a consistent downward trend in sales value.
Past data reveals that, after a stable period between 2017 and 2019, the market started to significantly shrink, particularly in 2020 with a substantial drop of -6.04%. This contraction persisted through the following years.
Forecasts for the period from 2024 to 2028 project the trend to continue, with expected average annual declines (CAGR) of about -1.1%, resulting in sales dipping further to €12.3 million by 2028. This forecasted 5-year growth rate amounts to an overall -5.38% reduction.
Future trends to watch for include potential shifts driven by new medical discoveries, changes in prescription practices, healthcare policy reforms, and the introduction of more effective or cost-efficient treatments that might absorb the segment currently held by antiarrhythmic medications.
